Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Ligand to Participate in September Investor Conferences
-
Ligand Announces Closing of Convertible Senior Notes Offering
-
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
-
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
-
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
-
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
-
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
-
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
-
JUPITER, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at...
-
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025